Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15008713 | 0.84 | CA12 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL15008668 | 0.84 | CA12 (0.36) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL15008108 | 0.84 | CA12 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL15024663 | 0.83 | CA12 (0.38) | CA12CA1CA2CA9 | |
| SCHEMBL2776266 | 0.82 | CA12 (0.39) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL15009297 | 0.81 | CA12 (0.52) | CA12CA1CA2CA9 | |
| SCHEMBL2776570 | 0.76 | CA12 (0.39) | CA12CA1CA2CA9ALDH1A1 | |
| Diethylamine SCHEMBL6370111 | 0.75 | MAPT (0.40) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL12355607 | 0.75 | CYP1A2 (0.30) | — | |
| SCHEMBL15024602 | 0.75 | CA12 (0.56) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663478-B2 | Benzotriazine oxides as drugs targeting Mycobacterium tuberculosis | SRI INTERNATIONAL (US) | 2017-05-30 | — | — | US | disclosed |
| US-20130150369-A1 | Benzotriazine Oxides as Drugs Targeting Mycobacterium Tuberculosis | SRI INTERNATIONAL (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150369-A1 | Benzotriazine Oxides as Drugs Targeting Mycobacterium Tuberculosis | QDPR, TBCA, TBCD | CA12 2505/4885CA1 4077/4885CA2 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.